Zafgen’s Prader-Willi syndrome therapy receives orphan drug designation in Europe

The European Commission (EC) has granted orphan drug designation to US-based Zafgen for its beloranib for treating Prader-Willi syndrome.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news